The US FDA has officially greenlit Novo Nordisk’s oral formulation of Wegovy (semaglutide), marking the arrival of the first daily pill in the GLP-1RA class specifically indicated for weight management and obesity.
-
Technological Edge: Transitioning from weekly injections to a once-daily tablet, this formulation offers greater flexibility and improves adherence, especially for patients with a fear of needles.
-
Clinical Performance: Results from the OASIS 4 Phase III trial demonstrated an average weight loss of 17%, significantly outperforming the placebo. The drug is also approved to reduce major adverse cardiovascular events (MACE) in overweight adults with established heart disease.
-
Market Strategy: Launching in early January 2026, the starting dose will be priced at $149 per month. This approval sent Novo’s shares up by 5%, providing a vital revenue stream as the company battles for market share.
-
Competitive Landscape: Novo’s lead may be brief, as Eli Lilly’s oral candidate, orforglipron, is expected to receive FDA approval in early Q1 2026. Industry analysts predict the oral obesity market will rapidly evolve into a dominant two-player dynamic between these two giants.